National Multicenter Study on the Prevalence of Carbapenemase-Producing Enterobacteriaceae in the Post-COVID-19 Era in Argentina: The RECAPT-AR Study
- PMID: 39766529
- PMCID: PMC11672406
- DOI: 10.3390/antibiotics13121139
National Multicenter Study on the Prevalence of Carbapenemase-Producing Enterobacteriaceae in the Post-COVID-19 Era in Argentina: The RECAPT-AR Study
Abstract
The COVID-19 pandemic has exacerbated the global antimicrobial resistance (AMR) crisis. Consequently, it is more urgent than ever to prioritize AMR containment and support countries in improving the detection, characterization, and rapid response to emerging AMR threats. We conducted a prospective, multicenter study to assess the prevalence of carbapenemase-producing Enterobacterales in infectious processes in Argentina during the post-COVID-19 pandemic period and explore therapeutic alternatives for their treatment (RECAPT-AR study).
Methods: A total of 182 hospitals participated by submitting Enterobacterales clinical isolates to the National Reference Laboratory (NRL) during the first three weeks of November 2021. Inclusion criteria were defined as an ertapenem MIC ≥ 0.5 mg/L, a zone diameter ≤ 22 mm. Carbapenemase genes and those coding for major extended-spectrum β-lactamases were molecularly characterized using multiplex PCR at the NRL. Antibiotic susceptibility testing followed international standards (CLSI and EUCAST).
Results: The NRL analyzed 821 Enterobacterales isolates. Metallo-β-lactamase (MBL, 42.0%) and KPC (39.8%) accounted for 81.8% of carbapenemases, followed by OXA-163 (7.4%), a variant of OXA-48 with additional activity against extended-spectrum cephalosporins, and enzyme combinations (8.3%). These combinations included NDM plus KPC (3.4%), OXA-163 plus KPC (2.4%), and OXA-163 plus NDM (2.1%). Klebsiella pneumoniae was the main species recovered, representing 76% of the isolates. According to the carbapenemase classes or combinations, tigecycline exhibited a susceptibility range of 33-83%, fosfomycin 59-81%, colistin 27-78%, and amikacin 17-81%. Ceftazidime-avibactam (CZA) and imipenem-relebactam (IMR) showed 92% and 98% susceptibility against serine carbapenemases, respectively. Meanwhile, aztreonam-avibactam (AZA) exhibited 96-98% susceptibility against all carbapenemase classes.
Conclusions: A new epidemiological landscape has emerged, characterized by the equivalent circulation of NDM and KPC. K. pneumoniae remains the primary species responsible for their dissemination. The co-production of carbapenemase combinations, particularly KPC plus NDM, was confirmed, mainly in K. pneumoniae. High activity was observed for AZA against MBLs and for CZA and IMR against KPC and OXA-163 carbapenemases.
Keywords: COVID-19; Enterobacterales; carbapenemase; metallo-β-lactamase.
Conflict of interest statement
All authors declare the absence of any conflicts of interest related to the submitted article.
Figures
Similar articles
-
Occurrence of multi-carbapenemase-producing Enterobacterales in a tertiary hospital in Madrid (Spain): A new epidemiologic scenario.J Glob Antimicrob Resist. 2024 Sep;38:281-291. doi: 10.1016/j.jgar.2024.06.012. Epub 2024 Jul 10. J Glob Antimicrob Resist. 2024. PMID: 38996870
-
In vitro activity of ceftazidime/avibactam and comparators against carbapenemase-producing Enterobacterales and Pseudomonas aeruginosa isolates collected globally between 2016 and 2018.J Glob Antimicrob Resist. 2021 Dec;27:132-141. doi: 10.1016/j.jgar.2021.08.010. Epub 2021 Sep 1. J Glob Antimicrob Resist. 2021. PMID: 34478880
-
Imipenem-Relebactam Susceptibility in Enterobacterales Isolates Recovered from ICU Patients from Spain and Portugal (SUPERIOR and STEP Studies).Microbiol Spectr. 2022 Oct 26;10(5):e0292722. doi: 10.1128/spectrum.02927-22. Epub 2022 Aug 31. Microbiol Spectr. 2022. PMID: 36043877 Free PMC article.
-
New β-Lactam-β-Lactamase Inhibitor Combinations.Clin Microbiol Rev. 2020 Nov 11;34(1):e00115-20. doi: 10.1128/CMR.00115-20. Print 2020 Dec 16. Clin Microbiol Rev. 2020. PMID: 33177185 Free PMC article. Review.
-
Epidemiology and Genetic Traits of Carbapenemase-Producing Enterobacterales: A Global Threat to Human Health.Antibiotics (Basel). 2025 Feb 1;14(2):141. doi: 10.3390/antibiotics14020141. Antibiotics (Basel). 2025. PMID: 40001385 Free PMC article. Review.
Cited by
-
From genomics to treatment: overcoming pan-drug-resistant Klebsiella pneumoniae in clinical settings.Front Pharmacol. 2025 May 30;16:1570278. doi: 10.3389/fphar.2025.1570278. eCollection 2025. Front Pharmacol. 2025. PMID: 40520176 Free PMC article.
-
Colistin Treatment Outcomes in Gram-Negative Bacterial Infections in the Northeast of Romania: A Decade of Change Through Pandemic Challenges.Antibiotics (Basel). 2025 Mar 7;14(3):275. doi: 10.3390/antibiotics14030275. Antibiotics (Basel). 2025. PMID: 40149086 Free PMC article.
-
Global Epidemiology and Antimicrobial Resistance of Klebsiella Pneumoniae Carbapenemase (KPC)-Producing Gram-Negative Clinical Isolates: A Review.Microorganisms. 2025 Jul 19;13(7):1697. doi: 10.3390/microorganisms13071697. Microorganisms. 2025. PMID: 40732206 Free PMC article. Review.
References
-
- WHO Bacterial Priority Pathogens List, 2024: Bacterial Pathogens of Public Health Importance to Guide Research, Development and Strategies to Prevent and Control Antimicrobial Resistance. World Health Organization; Geneva, Switzerland: 2024.
-
- Castanheira M., Deshpande L.M., Mendes R.E., Canton R., Sader H.S., Jones R.N. Variations in the Occurrence of Resistance Phenotypes and Carbapenemase Genes Among Enterobacteriaceae Isolates in 20 Years of the SENTRY Antimicrobial Surveillance Program. Open Forum Infect. Dis. 2019;6:S23–S33. doi: 10.1093/ofid/ofy347. - DOI - PMC - PubMed
-
- Pasteran F., Meo A., Gomez S., Derdoy L., Albronoz E., Faccone D., Guerriero L., Archuby D., Tarzia A., López M., et al. Emergence of Genetically Related NDM-1-Producing Providencia Rettgeri Strains in Argentina. J. Glob. Antimicrob. Resist. 2014;2:344–345. doi: 10.1016/j.jgar.2014.07.003. - DOI - PubMed
-
- Belder D.D., Lucero C., Rapoport M., Rosato A., Faccone D., Petroni A., Pasteran F., Albornoz E., Corso A., Gomez S.A. Genetic Diversity of KPC-Producing Escherichia coli, Klebsiella oxytoca, Serratia marcescens, and Citrobacter freundii Isolates from Argentina. Microb. Drug Resist. 2018;24:958–965. doi: 10.1089/mdr.2017.0213. - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials
Miscellaneous